No association was observed between ACE2 expression (IRS0 vs. IRS1-3) and the patients’ clinicopathological data (gender, TNM classification, tumor stage, differentiation, smoker, PD-L1 expression, and KRAS or EGFR mutation) although a trend was observed for a higher frequency of ACE2 expression in EGFR-mutant patients (p = 0.063). This evidence concerns the gene KRAS and neoplasm.